Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;406(1):249-65.
doi: 10.1007/s00216-013-7446-4. Epub 2013 Nov 20.

Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments

Affiliations

Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments

Anna Alekseeva et al. Anal Bioanal Chem. 2014 Jan.

Abstract

Periodate oxidation followed by borohydride reduction converts the well-known antithrombotics heparin and low-molecular-weight heparins (LMWHs) into their "glycol-split" (gs) derivatives of the "reduced oxyheparin" (RO) type, some of which are currently being developed as potential anti-cancer and anti-inflammatory drugs. Whereas the structure of gs-heparins has been recently studied, details of the more complex and more bioavailable gs-LMWHs have not been yet reported. We obtained RO derivatives of the three most common LMWHs (tinzaparin, enoxaparin, and dalteparin) and studied their structures by two-dimensional nuclear magnetic resonance spectroscopy and ion-pair reversed-phase high-performance liquid chromatography coupled with electrospray ionization mass spectrometry. The liquid chromatography-mass spectrometry (LC-MS) analysis was extended to their heparinase-generated oligosaccharides. The combined NMR/LC-MS analysis of RO-LMWHs provided evidence for glycol-splitting-induced transformations mainly involving internal nonsulfated glucuronic and iduronic acid residues (including partial hydrolysis with formation of "remnants") and for the hydrolysis of the gs uronic acid residues when formed at the non-reducing ends (mainly, in RO-dalteparin). Evidence for minor modifications, such as ring contraction of some dalteparin internal aminosugar residues, was also obtained. Unexpectedly, the N-sulfated 1,6-anhydromannosamine residues at the enoxaparin reducing end were found to be susceptible to the periodate oxidation. In addition, in tinzaparin and enoxaparin, the borohydride reduction converts the hemiacetalic aminosugars at the reducing end to alditols. Typical LC-MS signatures of RO-derivatives of individual LMWH both before and after digestion with heparinases included oligosaccharides generated from the original antithrombin-binding and "linkage" regions.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Simplified formula of a representative ATBR-containing chain of porcine mucosal heparin (a) and the corresponding glycol-split derivative (b) obtained by periodate oxidation and borohydride reduction of nonsulfated glucuronic (G/G′) and iduronic (I) residues, to generate gsG/gsG′, and gsI [13] LR = linkage region [23] at the “reducing” end (RE). The biochemical formula of ATBR is indicated in structure (a), starting with a residue I that is not part of the pentasaccharidic active site, but most often precedes it. Structure (a) is adapted from [22]; a major modification involves the ANS,6S residue at the non-reducing end (NRE), assumed to be the consequence of cleavage (by an endo-β-D-glucosidase) of a G-ANS6S glycosidic bond in the chains of the heparin proteoglycan precursor (“macromolecular heparin”). The structure of the “full” linkage region LR is reported in (c) and (d) for heparin and RO-heparin, respectively, where GLR is the G residue in the LR, Gal1 and Gal2 are two galactose residues, Xyl is xylose, Ser is serine [23]. The two glycol-split residues (gsGLR and gsXyl) in the LR of gs-heparin were not previously described (see text). Circled residues in the unmodified heparin structure (a) and (c) highlight unsubstituted diol groups susceptible of glycol-splitting
Fig. 2
Fig. 2
Simplified structures of tinzaparin, enoxaparin, and dalteparin Internal sequences are indicated as substantially the same as in non-depolymerized heparin. The end groups susceptible of being modified by periodate oxidation or borohydride reduction are circled
Fig. 3
Fig. 3
Anomeric (a) and “ring” (b) regions of the 1H/13C HSQC NMR spectra of RO-tinzaparin (red spots) superimposed on the spectrum of the corresponding unmodified LMWH (blue spots) Symbols for typical end-group signals are framed with rectangles A – glucosamine, A* – N-sulfate-glucosamine-3-O-sulfate, ΔU2S – 4,5-unsaturated 2-O-sulfated uronic acid, I/G – iduronic and glucuronic acids, GLR – glucuronic acid of the linkage region sequence, gsI/gsG – glycol-split iduronic and glucuronic acids, gsU – glycol-split uronic acids, Gal – galactose, Xyl – xylose, Ser - serine
Fig. 4
Fig. 4
LC-MS profiles of enoxaparin (a), RO-enoxaparin (c) and the corresponding expanded chromatograms (b, d) LC conditions: column C18 100 x 2.1 mm,.2.6 μm; eluents A and B – 10 mM DBA and 10 mM CH3COOH in H2O-CH3CN = 9:1 (v/v) and CH3CN, respectively; gradient: 0 min – 0%B, 5 min – 0%B, 130 min – 35%B, 140 min – 70%B, 145 min – 70%B, 148 min – 0%B, 170 min – 0%B; flow rate – 0.25 ml/min
Fig. 5
Fig. 5
Terminal residues at the non-reducing end (NRE) and at the reducing end (RE) confirmed or found for unmodified and RO-LMWHs NOTE: Since structures have been confirmed or elucidated by MS spectroscopy, the anionic groups (COOH, SO3H) are represented in their undissociated form
Fig. 6
Fig. 6
LC-MS chromatogram of the heparinase-digest of RO-enoxaparin LC conditions: column C18 100 x 2.1 mm, 2.6 μm; eluents A and B – 10 mM DBA and 10 mM CH3COOH in H2O-CH3OH = 9:1 (v/v) and CH3OH, respectively; 0 min – 17% B, 10 min – 17%B, 30 – 42%, 50 min – 50% B, 65 min – 90%, 75 min – 90%B, 76 min – 17% B, 95 min – 17 %B; flow rate – 0.1 ml/min; injection volume – 5 μl. Sodium borohydride reduction was used to distinguish between internal gs-unit and alditol end residue. For example, the double-charged ion with m/z 497.02 could correspond to both ΔU4,4,0,1gs and ΔU4,4,0-ol. After sodium borohydride reduction two peaks with m/z values were observed: a) m/z 498.02, indicating that this oligosaccharide containing one internal gs-unit (gsU), corresponds to the structure ΔUS-ANS6(S)-gsU-ANS6(S), where only one of the two sulfate groups within parenthesis is present; b) unmodified m/z 497.02, which should have an internal 2-O-sulfated uronic acid (US) and corresponds to ΔUS-ANS-US-A.olNS structure. The additional NaBH4 reduction of the RO-enoxaparin digest proved also the structure assigned to the minor tetrasaccharides terminating with an uronic acid remnant (ΔU4,4,1,1gs-R, m/z 577.03 for [M-2H]2− ion form, and ΔU4,5,0,1gs-R, m/z 596.01 for [M-2H]2− ion form), for which the m/z values remained constant after the additional reduction

Similar articles

Cited by

References

    1. Weitz JI. Low-molecular weight heparins. N Engl J Med. 1997;337:688–698. - PubMed
    1. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimentional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 2007;33:478–487. and references therein. - PubMed
    1. Casu B. In: Chemistry and Biology of Heparin and Heparan Sulfate. Garg HG, Linhardt RJ, Hales CA, editors. Elsevier; Amsterdam: 2005. and references therein.
    1. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov. 2002;1:140–148. - PubMed
    1. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic agents. Nat Rev Cancer. 2005;5:526–542. - PubMed

Publication types